RLAY Relay Therapeutics, Inc.
$18.35▼ -5.75%
Healthcare
Other
After hours
$18.22▼ -0.69%
Oct 30, 5:28 PM ET
Volume 3.60M
Avg Volume (10D) 1.99M
Key Metrics & Fundamentals
Market Cap
$4.02B
P/E Ratio
–
Div Yield
0.00%
52W Range
5.95 - 21.27
% vs 50 MA
-0.91%
% vs 200 MA
22.36%
RSI-14
50.0
MACD Histogram
+0.1800
Beta (1Y vs SPY)
1.48
Free Cash Flow
-$54.11M
Gross Rev
$350,000
Gross Profit
$350,000
EBITDA
-$90.46M
COGS
–
Operating Exp
$91.17M
Operating Income
-$90.82M
EBIT
-$90.82M
Pretax Income
-$83.71M
Net Income
-$83.71M
EPS (Diluted)
-0.41
Price & Volume History
Loading chart…
Recent News
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
GlobeNewswire · Oct 28, 2026 4:12 PM ET
Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?
Insider Monkey · Oct 28, 2026 9:16 AM ET
What Could Go Wrong With Recursion Pharmaceuticals Stock?
Trefis · Oct 8, 2026 7:58 PM ET
Relay Therapeutics Insider Sold Shares Worth $872,402, According to a Recent SEC Filing
MT Newswires · Oct 8, 2026 5:34 PM ET
Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing
MT Newswires · Oct 8, 2026 5:33 PM ET
Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value
Simply Wall St. · Oct 8, 2026 2:12 AM ET
Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?
Simply Wall St. · Oct 7, 2026 10:10 PM ET
Raymond James Updates Healthcare Top Picks for October
Investing.com · Oct 1, 2026 4:26 PM ET
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Zacks · Sep 24, 2026 11:08 AM ET
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
GlobeNewswire · Sep 22, 2026 9:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RLAY's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.